No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
OVID240719C2500
- 0.05
- 0.000.00%
15min DelayClose Jul 5 14:28 ET
0.05High0.05Low
0.05Open0.05Pre Close240 Volume133 Open Interest2.50Strike Price1.20KTurnover477.94%IV242.28%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier13DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.1925Delta0.4024Gamma14.91Leverage Ratio-0.0069Theta0.0000Rho2.87Eff Leverage0.0004Vega
Intraday
- 5D
- Daily
News
TD Cowen Maintains Ovid Therapeutics(OVID.US) With Buy Rating
TD Cowen analyst Ritu Baral maintains $Ovid Therapeutics(OVID.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 44.8% and a total average return of 8.2% over the pas
A Quick Look at Today's Ratings for Ovid Therapeutics(OVID.US), With a Forecast Between $2 to $5
On Jul 02, major Wall Street analysts update their ratings for $Ovid Therapeutics(OVID.US)$, with price targets ranging from $2 to $5.TD Cowen analyst Ritu Baral maintains with a buy rating.BTIG analy
TD Cowen Sticks to Its Buy Rating for Ovid Therapeutics (OVID)
HC Wainwright & Co. Reiterates Buy on Ovid Therapeutics, Maintains $3 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Ovid Therapeutics (NASDAQ:OVID) with a Buy and maintains $3 price target.
Ovid Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/02/2024 252.94% HC Wainwright & Co. $3 → $3 Reiterates Buy → Buy 06/18/2024 488.24% BTIG $11 → $5 Maint
Buy Rating Affirmed for Ovid Therapeutics Following Promising Phase 1 Results of OV888/GV101
Comments
$Ovid Therapeutics(OVID.US$ why the super dump?
1
1
$Ovid Therapeutics(OVID.US$
Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations
Ovid Therapeutics and Graviton Bioscience announced positive Phase 1 trial results for their OV888/GV101 capsule, a potential first-in-class therapy for cerebral cavernous malformations (CCM). The trial met its primary objective by demonstrating a favorable safety and to...
Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations
Ovid Therapeutics and Graviton Bioscience announced positive Phase 1 trial results for their OV888/GV101 capsule, a potential first-in-class therapy for cerebral cavernous malformations (CCM). The trial met its primary objective by demonstrating a favorable safety and to...
1
$Ovid Therapeutics(OVID.US$
Ovid Therapeutics Reports on Takeda’s Announcement of Phase 3 Topline Study Results for Soticlestat
Ovid Therapeutics reported on Takeda's Phase 3 study results for soticlestat, a treatment for Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS). The Skyline study in DS narrowly missed its primary endpoint but showed significant effects in secondary endpoints with p-values ≤ 0.008. The Skyway study in LGS missed its primary endpoint. Soticlestat had a favorabl...
Ovid Therapeutics Reports on Takeda’s Announcement of Phase 3 Topline Study Results for Soticlestat
Ovid Therapeutics reported on Takeda's Phase 3 study results for soticlestat, a treatment for Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS). The Skyline study in DS narrowly missed its primary endpoint but showed significant effects in secondary endpoints with p-values ≤ 0.008. The Skyway study in LGS missed its primary endpoint. Soticlestat had a favorabl...
1
Soticlestat's potential in treating Lennox-Gastaut and Dravet syndromes is backed by Ovid and Ligand's deal. Ligand sees the deal aligning with its strategy of investing in solutions answering high unmet needs, promising high-margin growth for its investors.
$Castor Maritime(CTRM.US$
Positions Details
I hope everyone had a good day on the markets. When the stock drops and you get that urge to sell. HOLD we can’t stop these short sellers from manipulation unless we stay bullish and stop selling out of fear. When they dip buy more.
I have bags of $Ovid Therapeutics(OVID.US$ I have bags and contracts with $SOS Ltd(SOS.US$ up a total today of 1130% $Castor Maritime(CTRM.US$ is great see major potential in the future. $Super League Gaming Inc(SLGG.US$
Positions Details
I hope everyone had a good day on the markets. When the stock drops and you get that urge to sell. HOLD we can’t stop these short sellers from manipulation unless we stay bullish and stop selling out of fear. When they dip buy more.
I have bags of $Ovid Therapeutics(OVID.US$ I have bags and contracts with $SOS Ltd(SOS.US$ up a total today of 1130% $Castor Maritime(CTRM.US$ is great see major potential in the future. $Super League Gaming Inc(SLGG.US$
loading...
5
Read more
Mcsnacks H Tupack : They reduced their workforce